{"id":16611,"date":"2023-03-15T10:12:02","date_gmt":"2023-03-15T14:12:02","guid":{"rendered":"https:\/\/www.progeriaresearch.org\/?p=16611"},"modified":"2025-02-15T17:46:23","modified_gmt":"2025-02-15T22:46:23","slug":"progerinbiomarker","status":"publish","type":"post","link":"https:\/\/www.progeriaresearch.org\/nl\/2023\/03\/15\/progerinbiomarker\/","title":{"rendered":"Spannende onderzoeksmijlpalen in de evaluatie van behandelingen en levensverlenging!"},"content":{"rendered":"

[et_pb_section fb_built=\u201d1\u2033 _builder_version=\u201d4.16\u2033 custom_padding=\u201d0px|||||\u201d global_colors_info=\u201d{}\u201d][et_pb_row _builder_version=\u201d4.16\u2033 background_size=\u201dinitial\u201d background_position=\u201dtop_left\u201d background_repeat=\u201drepeat\u201d custom_padding=\u201d||5px|||\u201d global_colors_info=\u201d{}\u201d][et_pb_column type=\u201d4_4\u2033 _builder_version=\u201d4.16\u2033 custom_padding=\u201d|||\u201d global_colors_info=\u201d{}\u201d custom_padding__hover=\u201d|||\u201d][et_pb_text _builder_version=\u201d4.24.0\u2033 background_size=\u201dinitial\u201d background_position=\u201dtop_left\u201d background_repeat=\u201drepeat\u201d global_colors_info=\u201d{}\u201d]<\/p>\n

We zijn verheugd om twee spannende onderzoeksupdates met u te delen, die vandaag online zijn gepubliceerd in 's werelds beste cardiovasculaire tijdschrift, Circulatie (1)<\/a><\/em>:<\/h5>\n

 <\/p>\n

\"\"<\/p>\n

Biomarker bij Progeria<\/u><\/strong><\/span><\/p>\n

Een nieuwe manier om progerine te meten, het toxische eiwit dat Progeria veroorzaakt, is ontwikkeld door een team onder leiding van PRF medeoprichter en medisch directeur, Dr. Leslie Gordon. Met de ontdekking van deze biomarker, die bloedplasma gebruikt om progerineniveaus te meten, onderzoekers kunnen na een kortere tijdsperiode begrijpen hoe behandelingen deelnemers aan klinische proeven be\u00efnvloeden<\/strong> en op meerdere punten tijdens elke klinische proef.<\/p>\n

Deze test kan het klinische proefproces optimaliseren door: het verstrekken van vroege informatie over de effectiviteit van de behandelingen die worden getest<\/strong>, als een aanloop naar andere klinische tests zoals gewichtstoename, dermatologische veranderingen, gewrichtscontractuur en -functie, enz., die allemaal veel meer tijd nodig hebben om zich te manifesteren. Deze klinische kenmerken van Progeria zijn belangrijke langetermijnmetingen van behandelingseffecten die nu worden aangevuld met de progerineniveaus die eerder in de therapie zijn gemeten. We kunnen nu mogelijk al vier maanden na het starten van de behandeling de voordelen van de behandeling begrijpen, of een behandeling stoppen die de proefdeelnemer mogelijk niet ten goede komt, om onnodige bijwerkingen te voorkomen.<\/p>\n

Nog langere levens met lonafarnib<\/u><\/span><\/strong><\/p>\n

Deze nieuwe en innovatieve manier om progerine te meten, versnelt niet alleen toekomstige ontdekkingen op het gebied van behandelingen en genezingen, maar geeft ook aan dat de Het langetermijnvoordeel van lonafarnib voor kinderen met Progeria is groter dan eerder vastgesteld<\/strong>.<\/p>\n

Onderzoeksgegevens geven aan dat lagere progerinespiegels in het bloed overlevingsvoordelen weerspiegelen: hoe langer iemand met Progeria lonafarnib bleef gebruiken, hoe groter het overlevingsvoordeel van de therapie. Progerinespiegels werden met ongeveer 30-60% verlaagd zolang het medicijn werd ingenomen, en de levensverwachting van pati\u00ebnten die meer dan 10 jaar in behandeling waren, nam gemiddeld met 4,5 jaar toe. Dat is meer dan een 30% toename van de gemiddelde levensduur, van 14,5 jaar tot bijna 20 jaar<\/strong>!<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=\u201d4.16\u2033 background_size=\u201dinitial\u201d background_position=\u201dtop_left\u201d background_repeat=\u201drepeat\u201d global_colors_info=\u201d{}\u201d][et_pb_column type=\u201d4_4\u2033 _builder_version=\u201d4.16\u2033 custom_padding=\u201d|||\u201d global_colors_info=\u201d{}\u201d custom_padding__hover=\u201d|||\u201d][et_pb_button button_url=\u201dhttps:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2023\/03\/Progerin-Plasma-Biomarker-press-release-FINAL.pdf\u201d button_text=\u201dLees ons persbericht hier voor meer informatie\u201d button_alignment=\u201dcenter\u201d admin_label=\u201dbiomarker pdf\u201d _builder_version=\u201d4.19.5\u2033 _module_preset=\u201ddefault\u201d button_text_color=\u201d#FFFFFF\u201d button_bg_color=\u201d#00B2E2\u2033 button_border_width=\u201d0px\u201d button_border_color=\u201d#00B2E2\u2033 background_layout=\u201ddark\u201d global_colors_info=\u201d{}\u201d][\/et_pb_button][et_pb_text _builder_version=\u201d4.19.5\u2033 _module_preset=\u201ddefault\u201d global_colors_info=\u201d{}\u201d]<\/p>\n

\u201cEen van de meest opmerkelijke verhalen die ooit in deze podcast is gedeeld\u201d
<\/strong>\u2013 Dr. Carolyn Lam, wereldberoemd hartspecialist en gastheer van de podcast Circulatie op de vlucht, <\/em>over de reis die leidde tot deze opwindende bevindingen. <\/em>Luister naar het volledige interview<\/strong> over de diepgaande impact van deze studie rechtstreeks van Dr. Gordon. Luister hier<\/strong><\/a> (<\/a>vanaf 6:41).<\/p>\n

[\/et_pb_text][et_pb_button button_url=\u201dhttps:\/\/circulation.libsyn.com\/circulation-june-6-2023-issue\u201d button_text=\u201dLuister naar Dr. Leslie Gordon in de Circulation on the Run podcast\u201d button_alignment=\u201dcenter\u201d admin_label=\u201dcirculation podcast\u201d _builder_version=\u201d4.19.5\u2033 _module_preset=\u201ddefault\u201d button_text_color=\u201d#FFFFFF\u201d button_bg_color=\u201d#00B2E2\u2033 button_border_width=\u201d0px\u201d button_border_color=\u201d#00B2E2\u2033 background_layout=\u201ddark\u201d global_colors_info=\u201d{}\u201d][\/et_pb_button][et_pb_text _builder_version=\u201d4.19.5\u2033 _module_preset=\u201ddefault\u201d] global_colors_info=\u201d{}\u201d]<\/p>\n

En in juni verschenen er twee redactionele artikelen (2) <\/a>En (3)<\/a> werden gepubliceerd in Circulatie <\/i>Hiermee wordt het cruciale belang van deze biomarker voor het verbeteren van behandelingen en genezing van kinderen met Progeria benadrukt, en voor een beter begrip van veroudering.<\/p>\n

[\/et_pb_text][et_pb_text admin_label=\u201dpapers\u201d module_id=\u201d1\u2033 _builder_version=\u201d4.19.5\u2033 background_size=\u201dinitial\u201d background_position=\u201dtop_left\u201d background_repeat=\u201drepeat\u201d global_colors_info=\u201d{}\u201d]<\/p>\n

\"\"<\/p>\n

 <\/p>\n

\n

(1) Gordon, LB, Norris, W., Hamren, S., et al<\/em>Plasma Progerine bij pati\u00ebnten met Hutchinson-Gilford Progeria-syndroom: immunoassay-ontwikkeling en klinische evaluatie. Circulatie<\/em>, 2023<\/p>\n

(2) Progressie van hartafwijkingen bij het Hutchinson-Gilford Progeria-syndroom: een prospectieve longitudinale studie.<\/a>
Olsen FJ, Gordon LB, Smoot L, Kleinman ME, Gerhard-Herman M, Hegde SM, Mukundan S, Mahoney T, Massaro J, Ha S, Prakash A.
Circulatie<\/em>. 2023 6 juni;147(23):1782-1784. doi: 10.1161\/CIRCULATIONAHA.123.064370. Epub 2023 5 juni.<\/p>\n

(3) Gemakkelijk beschikbare hulpmiddelen om progerine en progressie van hartziekten bij het Hutchinson-Gilford Progeria-syndroom te detecteren. <\/a>
Eriksson M, Haugaa K, Rev\u00eachon G.
Circulatie<\/em>. 2023 6 juni;147(23):1745-1747. doi: 10.1161\/CIRCULATIONAHA.123.064765. Epub 2023 5 juni.<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>","protected":false},"excerpt":{"rendered":"

Ons onderzoeksteam heeft een essenti\u00eble nieuwe manier ontdekt om progerine te meten, het toxische eiwit dat Progeria veroorzaakt. Met deze ontdekking ontdekten wetenschappers ook dat het langetermijnvoordeel van lonafarnib voor kinderen met Progeria groter is dan we dachten.
\nWat betekenen deze twee bevindingen voor de Progeria-gemeenschap? <\/p>","protected":false},"author":2,"featured_media":16614,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":"","_links_to":"","_links_to_target":""},"categories":[2,1],"tags":[],"class_list":["post-16611","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-uncategorized"],"yoast_head":"\nProgerin Biomarker | The Progeria Research Foundation<\/title>\n<meta name=\"description\" content=\"Our research team has discovered a vital new way to measure progerin, the toxic protein that causes Progeria. With this discovery, scientists also found that the long-term benefit of lonafarnib for children with Progeria is greater than we thought. What do these two findings mean for the Progeria community? Read more here\u2026\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.progeriaresearch.org\/nl\/2023\/03\/15\/progerinbiomarker\/\" \/>\n<meta property=\"og:locale\" content=\"nl_NL\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Progerin Biomarker | The Progeria Research Foundation\" \/>\n<meta property=\"og:description\" content=\"Our research team has discovered a vital new way to measure progerin, the toxic protein that causes Progeria. With this discovery, scientists also found that the long-term benefit of lonafarnib for children with Progeria is greater than we thought. What do these two findings mean for the Progeria community? Read more here\u2026\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.progeriaresearch.org\/nl\/2023\/03\/15\/progerinbiomarker\/\" \/>\n<meta property=\"og:site_name\" content=\"The Progeria Research Foundation\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ProgeriaResearch\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-15T14:12:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-15T22:46:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2023\/03\/Sammy-7.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"640\" \/>\n\t<meta property=\"og:image:height\" content=\"480\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Karen Betournay\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@Progeria\" \/>\n<meta name=\"twitter:site\" content=\"@Progeria\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Karen Betournay\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.progeriaresearch.org\/2023\/03\/15\/progerinbiomarker\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/2023\/03\/15\/progerinbiomarker\/\"},\"author\":{\"name\":\"Karen Betournay\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/2be6cec85c11aaef7a7602636c5b9946\"},\"headline\":\"Exciting research milestones in treatment evaluation and life extension!\",\"datePublished\":\"2023-03-15T14:12:02+00:00\",\"dateModified\":\"2025-02-15T22:46:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/2023\/03\/15\/progerinbiomarker\/\"},\"wordCount\":795,\"publisher\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/2023\/03\/15\/progerinbiomarker\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2023\/03\/Sammy-7.jpg\",\"articleSection\":[\"News\",\"Uncategorized\"],\"inLanguage\":\"nl-NL\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.progeriaresearch.org\/2023\/03\/15\/progerinbiomarker\/\",\"url\":\"https:\/\/www.progeriaresearch.org\/2023\/03\/15\/progerinbiomarker\/\",\"name\":\"Progerin Biomarker | The Progeria Research Foundation\",\"isPartOf\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/2023\/03\/15\/progerinbiomarker\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/2023\/03\/15\/progerinbiomarker\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2023\/03\/Sammy-7.jpg\",\"datePublished\":\"2023-03-15T14:12:02+00:00\",\"dateModified\":\"2025-02-15T22:46:23+00:00\",\"description\":\"Our research team has discovered a vital new way to measure progerin, the toxic protein that causes Progeria. With this discovery, scientists also found that the long-term benefit of lonafarnib for children with Progeria is greater than we thought. What do these two findings mean for the Progeria community? Read more here\u2026\",\"breadcrumb\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/2023\/03\/15\/progerinbiomarker\/#breadcrumb\"},\"inLanguage\":\"nl-NL\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.progeriaresearch.org\/2023\/03\/15\/progerinbiomarker\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\/\/www.progeriaresearch.org\/2023\/03\/15\/progerinbiomarker\/#primaryimage\",\"url\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2023\/03\/Sammy-7.jpg\",\"contentUrl\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2023\/03\/Sammy-7.jpg\",\"width\":640,\"height\":480},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.progeriaresearch.org\/2023\/03\/15\/progerinbiomarker\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.progeriaresearch.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Exciting research milestones in treatment evaluation and life extension!\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#website\",\"url\":\"https:\/\/www.progeriaresearch.org\/ta\/\",\"name\":\"The Progeria Research Foundation\",\"description\":\"For the Children \u2665 For the Cure\",\"publisher\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.progeriaresearch.org\/ta\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"nl-NL\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#organization\",\"name\":\"The Progeria Research Foundation\",\"url\":\"https:\/\/www.progeriaresearch.org\/ta\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png\",\"contentUrl\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png\",\"width\":300,\"height\":86,\"caption\":\"The Progeria Research Foundation\"},\"image\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/ProgeriaResearch\/\",\"https:\/\/x.com\/Progeria\",\"https:\/\/www.instagram.com\/progeriaresearch\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/2be6cec85c11aaef7a7602636c5b9946\",\"name\":\"Karen Betournay\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g\",\"caption\":\"Karen Betournay\"},\"url\":\"https:\/\/www.progeriaresearch.org\/nl\/author\/karenb\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Progerin Biomarker | The Progeria Research Foundation","description":"Our research team has discovered a vital new way to measure progerin, the toxic protein that causes Progeria. With this discovery, scientists also found that the long-term benefit of lonafarnib for children with Progeria is greater than we thought. What do these two findings mean for the Progeria community? Read more here\u2026","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.progeriaresearch.org\/nl\/2023\/03\/15\/progerinbiomarker\/","og_locale":"nl_NL","og_type":"article","og_title":"Progerin Biomarker | The Progeria Research Foundation","og_description":"Our research team has discovered a vital new way to measure progerin, the toxic protein that causes Progeria. With this discovery, scientists also found that the long-term benefit of lonafarnib for children with Progeria is greater than we thought. What do these two findings mean for the Progeria community? Read more here\u2026","og_url":"https:\/\/www.progeriaresearch.org\/nl\/2023\/03\/15\/progerinbiomarker\/","og_site_name":"The Progeria Research Foundation","article_publisher":"https:\/\/www.facebook.com\/ProgeriaResearch\/","article_published_time":"2023-03-15T14:12:02+00:00","article_modified_time":"2025-02-15T22:46:23+00:00","og_image":[{"width":640,"height":480,"url":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2023\/03\/Sammy-7.jpg","type":"image\/jpeg"}],"author":"Karen Betournay","twitter_card":"summary_large_image","twitter_creator":"@Progeria","twitter_site":"@Progeria","twitter_misc":{"Written by":"Karen Betournay","Est. reading time":"3 minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.progeriaresearch.org\/2023\/03\/15\/progerinbiomarker\/#article","isPartOf":{"@id":"https:\/\/www.progeriaresearch.org\/2023\/03\/15\/progerinbiomarker\/"},"author":{"name":"Karen Betournay","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/2be6cec85c11aaef7a7602636c5b9946"},"headline":"Exciting research milestones in treatment evaluation and life extension!","datePublished":"2023-03-15T14:12:02+00:00","dateModified":"2025-02-15T22:46:23+00:00","mainEntityOfPage":{"@id":"https:\/\/www.progeriaresearch.org\/2023\/03\/15\/progerinbiomarker\/"},"wordCount":795,"publisher":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#organization"},"image":{"@id":"https:\/\/www.progeriaresearch.org\/2023\/03\/15\/progerinbiomarker\/#primaryimage"},"thumbnailUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2023\/03\/Sammy-7.jpg","articleSection":["News","Uncategorized"],"inLanguage":"nl-NL"},{"@type":"WebPage","@id":"https:\/\/www.progeriaresearch.org\/2023\/03\/15\/progerinbiomarker\/","url":"https:\/\/www.progeriaresearch.org\/2023\/03\/15\/progerinbiomarker\/","name":"Progerin Biomarker | The Progeria Research Foundation","isPartOf":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.progeriaresearch.org\/2023\/03\/15\/progerinbiomarker\/#primaryimage"},"image":{"@id":"https:\/\/www.progeriaresearch.org\/2023\/03\/15\/progerinbiomarker\/#primaryimage"},"thumbnailUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2023\/03\/Sammy-7.jpg","datePublished":"2023-03-15T14:12:02+00:00","dateModified":"2025-02-15T22:46:23+00:00","description":"Our research team has discovered a vital new way to measure progerin, the toxic protein that causes Progeria. With this discovery, scientists also found that the long-term benefit of lonafarnib for children with Progeria is greater than we thought. What do these two findings mean for the Progeria community? Read more here\u2026","breadcrumb":{"@id":"https:\/\/www.progeriaresearch.org\/2023\/03\/15\/progerinbiomarker\/#breadcrumb"},"inLanguage":"nl-NL","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.progeriaresearch.org\/2023\/03\/15\/progerinbiomarker\/"]}]},{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/www.progeriaresearch.org\/2023\/03\/15\/progerinbiomarker\/#primaryimage","url":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2023\/03\/Sammy-7.jpg","contentUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2023\/03\/Sammy-7.jpg","width":640,"height":480},{"@type":"BreadcrumbList","@id":"https:\/\/www.progeriaresearch.org\/2023\/03\/15\/progerinbiomarker\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.progeriaresearch.org\/"},{"@type":"ListItem","position":2,"name":"Exciting research milestones in treatment evaluation and life extension!"}]},{"@type":"WebSite","@id":"https:\/\/www.progeriaresearch.org\/ta\/#website","url":"https:\/\/www.progeriaresearch.org\/ta\/","name":"De Progeria Research Stichting","description":"Voor de kinderen \u2665 Voor de genezing","publisher":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.progeriaresearch.org\/ta\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"nl-NL"},{"@type":"Organization","@id":"https:\/\/www.progeriaresearch.org\/ta\/#organization","name":"De Progeria Research Stichting","url":"https:\/\/www.progeriaresearch.org\/ta\/","logo":{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/","url":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png","contentUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png","width":300,"height":86,"caption":"The Progeria Research Foundation"},"image":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ProgeriaResearch\/","https:\/\/x.com\/Progeria","https:\/\/www.instagram.com\/progeriaresearch\/"]},{"@type":"Person","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/2be6cec85c11aaef7a7602636c5b9946","name":"Karen Betournay","image":{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g","caption":"Karen Betournay"},"url":"https:\/\/www.progeriaresearch.org\/nl\/author\/karenb\/"}]}},"_links":{"self":[{"href":"https:\/\/www.progeriaresearch.org\/nl\/wp-json\/wp\/v2\/posts\/16611","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.progeriaresearch.org\/nl\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.progeriaresearch.org\/nl\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/nl\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/nl\/wp-json\/wp\/v2\/comments?post=16611"}],"version-history":[{"count":0,"href":"https:\/\/www.progeriaresearch.org\/nl\/wp-json\/wp\/v2\/posts\/16611\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/nl\/wp-json\/wp\/v2\/media\/16614"}],"wp:attachment":[{"href":"https:\/\/www.progeriaresearch.org\/nl\/wp-json\/wp\/v2\/media?parent=16611"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/nl\/wp-json\/wp\/v2\/categories?post=16611"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/nl\/wp-json\/wp\/v2\/tags?post=16611"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}